Latest Tax Refunds News

Patrys Limited has completed a modest capital raise and restructured its leadership as it advances its deoxymab antibody program, with a larger entitlement offer announced to fund clinical development and business growth.

Anatara Lifesciences reports Phase II GaRP-IBS trial results showing no safety concerns but missing the primary efficacy endpoint, while securing key patents and receiving a significant R&D tax refund.

Anatara Lifesciences has received nearly $1 million from the Australian Government’s R&D tax incentive, providing a vital capital injection to advance its Anti-Obesity pre-clinical studies.

Stanmore Resources has reported a robust recovery in its June quarter operations with increased coal production, zero serious safety incidents, and positive cash flow, despite challenging weather conditions. The company maintains its full-year production guidance, signaling resilience amid market uncertainties.

Antares Metals has reported promising exploration progress at its Mt Isa North project, revealing new copper mineralisation zones and multiple high-priority uranium targets. The discoveries set the stage for further drilling and resource definition.

Elixir Energy has advanced its strategic plan in Queensland’s Taroom Trough, appointing a new COO, initiating a major cost reduction, and preparing to drill key exploration and appraisal wells that could unlock significant gas resources.

Norwood Systems delivered its strongest quarter yet with record cash inflows, significant debt reduction, and expanding global partnerships, setting a robust foundation for FY2026.

Omega Oil & Gas has secured a $7.3 million refundable R&D tax offset for FY23, bolstering its financial position and supporting ongoing development of its promising Canyon Project in Queensland.

Imugene Limited has received a $5.87 million R&D tax refund, reinforcing its capacity to advance clinical trials in immuno-oncology. This funding milestone supports the development of its innovative cancer therapies, including CAR T cell treatments and oncolytic virotherapy.

Lindian Resources has secured a combined $1.65 million cash inflow from the exercise of unlisted options and a government R&D tax refund, strengthening its financial position for advancing the Kangankunde Rare Earths Project.

TruScreen Group Limited has launched a NZ$1.22 million Share Purchase Plan offering discounted shares to eligible investors, aiming to fuel growth in key international markets and public health initiatives.

Careteq Limited faces a significant repayment demand from the ATO over R&D tax claims but is mounting a formal objection backed by legal counsel.